Fecal Microbiota(University of Pittsburgh)(Fecal Microbiota(University of Pittsburgh)) - 在研适应症：非小细胞肺癌，PD-L1阳性肺癌，黑色素瘤_专利_临床

概要

基本信息

药物类型

粪菌移植

别名-

靶点-

作用机制

细菌替代物、微生物调节剂

治疗领域

肿瘤呼吸系统疾病皮肤和肌肉骨骼疾病

在研适应症

非小细胞肺癌PD-L1阳性肺癌黑色素瘤

非在研适应症-

原研机构

University of Pittsburgh

在研机构

University of Pittsburgh

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Fecal Microbiota(University of Pittsburgh) 相关的临床试验

NCT06030037 / Not yet recruiting临床2期IIT

Randomized Phase II Study of Pembrolizumab/Lenvatinib With and Without Responder-derived FMT (R-FMT) in Relapsed/Refractory Melanoma

In this is a randomized phase II study the addition of R-FMT to pembrolizumab /lenvatinib in PD-1 R/R melanoma will be evaluated over a 104-week period in patients with anti-PD-1 R/R disease. Patients with PD-1 refractory advanced melanoma are eligible to enroll, excluding patients with prior lenvatinib (or other TKI) exposure. Intestinal microbiome composition mediates response to anti-PD-1 by affecting systemic inflammatory tone.

开始日期2024-11-30

申办/合作机构

University of Pittsburgh

[+2]

NCT05669846 / Not yet recruiting临床2期IIT

Phase II Feasibility Study of Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC

This study is to determine if a fecal microbiota transplant (FMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.

开始日期2024-11-30

申办/合作机构

University of Pittsburgh

[+1]

NCT03341143 / Completed临床2期IIT

Phase II Feasibility Study of Fecal Microbiota Transplant (FMT) in Advanced Melanoma Patients Not Responding to PD-1 Blockade

The main goal of this research study is to determine if the fecal microbiota transplant (FMT) improves the body's ability to fight your cancer.

开始日期2018-03-19

申办/合作机构

Merck Sharp & Dohme Corp.

100 项与 Fecal Microbiota(University of Pittsburgh) 相关的临床结果

登录后查看更多信息

100 项与 Fecal Microbiota(University of Pittsburgh) 相关的转化医学

登录后查看更多信息

100 项与 Fecal Microbiota(University of Pittsburgh) 相关的专利（医药）

登录后查看更多信息

1

项与 Fecal Microbiota(University of Pittsburgh) 相关的文献（医药）

1998-01-01·Thrombosis and Haemostasis2区 · 医学

Recombinant Antitrypsin Pittsburgh Undergoes Proteolytic Cleavage during E. coli Sepsis and Fails to Prevent the Associated Coagulopathy in a Primate Model

2区 · 医学

Article

作者: Harper, P. L. ; Colman, R. W. ; Courtney, M. ; De La Cadena, R. A. ; Taylor, F. B. ; Carrell, R. W.

SummaryDuring severe sepsis there is dramatic activation of both contact pro-teases and the coagulation pathway. These processes contribute to the development of shock and disseminated intravascular coagulation (DIC) respectively. The Pittsburgh mutant of antitrypsin (358Met-Arg) is a novel protease inhibitor with activity against both thrombin and the contact proteases and should therefore prove beneficial as a therapeutic agent in the management of septic shock. This hypothesis was supported by an earlier study in a pig model where recombinant antitrypsin Pittsburgh (rAT Pittsburgh) at a concentration of 1 μM alleviated some of the features of shock, but did not improve survival. In order to reduce the lethal effects of E. coli sepsis we postulated that a higher concentration of antitrypsin Pittsburgh would be necessary. To test this hypothesis we used rAT Pittsburgh in a primate model. This was chosen in preference to another species as E. coli sepsis in the primate has been well characterised and closely resembles the changes seen in man.Surprisingly this treatment did not alleviate the features of shock and unexpectedly appeared to exacerbate the associated coagulopathy. We propose two possible mechanisms for this unforeseen outcome. The first results from the broad spectrum of activity of antitrypsin Pittsburgh. As well as inhibiting thrombin and the contact proteases, the Pittsburgh mutant also inhibits activated protein C. Inhibition of the protein C system is known to exacerbate septic shock. Secondly, a significant quantity of inactive antitrypsin Pittsburgh, cleaved at the reactive centre, was detected in the plasma of the treated animals. Proteolytically altered serpins, including antitrypsin, have been shown to enhance the inflammatory process. Therefore the accumulation of cleaved rAT Pittsburgh might be expected to exacerbate septic shock.

100 项与 Fecal Microbiota(University of Pittsburgh) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非小细胞肺癌	临床2期	美国	University of Pittsburgh	2024-11-30
PD-L1阳性肺癌	临床2期	美国	University of Pittsburgh	2024-11-30
黑色素瘤	临床2期	美国	University of Pittsburgh	2018-03-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03341143 (CTgov)	临床2期	黑色素瘤	20	Fecal Microbiota Transplant+Pembrolizumab	(遞網選網膚範積糧製夢) = 壓齋餘窪艱鏇繭遞鏇積製夢蓋窪齋廠餘選觸積 (鹽鏇製範願構襯鹽廠獵, 蓋鬱憲淵簾顧餘鹽窪積 ~ 觸壓衊鏇壓艱膚衊觸觸) 更多	-	2024-10-30